A three-outcome design for phase II clinical trials

Area of Science:

• Clinical Trials Methodology
• Biostatistics
• Drug Development

Background:

• Phase II trials assess treatment activity and tolerability to guide further study.
• Traditional phase II trials use a two-outcome hypothesis testing framework (reject null or alternative hypothesis).
• Borderline results in standard phase II trials create ambiguity in treatment progression decisions.

Purpose of the Study:

• To propose and describe an alternative phase II clinical trial design.
• To introduce a three-outcome framework: reject null hypothesis, reject alternative hypothesis, or reject neither.
• To address decision-making challenges with borderline treatment activity.

Main Methods:

• Development of a theoretical framework for a three-outcome trial design.
• Illustration of the design's properties with clinical examples.
• Focus on the clinical implications and practical application of the proposed design.

Main Results:

• The proposed design allows for three distinct outcomes, unlike the traditional two.
• This framework provides clearer guidance for borderline cases in phase II trials.
• Theoretical properties and clinical relevance of the three-outcome design are detailed.

Conclusions:

• The three-outcome design offers a more nuanced approach to phase II clinical trial decision-making.
• It enhances clarity for borderline treatment efficacy, optimizing drug development.
• This alternative design supports more informed decisions regarding advancing treatments to phase III studies.